Our Commitment
At the Thoracic Oncology Group of Australasia (TOGA), we are committed to improving lung cancer treatment and survival. Through the design of world-class research and trials, we hope to give you access to advanced treatment.
Support us
Inspire lung cancer patients through funding research and trials.
Impactful education
An education program to better equip you to implement new findings into your care.
Join us
Be part of TOGA and share a mission to prevent, treat, and cure thoracic cancer.
Research ideas
Our expert review process assists in developing high-quality funding applications.
Key Statistics About Thoracic Cancer
Every
0
minutes
a person living with lung cancer in Australia loses their life.
0
+
healthcare
professionals
empowered to integrate research findings into standard of care.
0
patients
were tested during the ASPiRATION trial, resulting in life-saving interventions.
Featured News
Clinical trials are the bedrock of this progress, driving the development of new and more effective treatments that can significantly improve the lives of individuals
An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients
An observational cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients
TOGA is excited to be part of the European Thoracic Oncology Platform (ETOP) ADOPT-Lung clinical trial, with recruitment expected to open towards the end of
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionize the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
